{"transactions":[{"id":745822,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":40388,"kind":"person","name":"Molineaux Christopher P.","position":1,"cik":"0001654773","reported_name":"Molineaux Christopher P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2026-06-08T20:15:14.000Z","date":"2026-06-05","kind":"exercise","planned":false,"acquired":false,"shares":11580,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The shares underlying these restricted stock units vested on June 5, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The shares underlying these restricted stock units vested on June 5, 2026."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":11580},"source":{"system":"sec-edgar","filing":"0001654773-26-000003","document":"form4-06082026_040610.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000165477326000003/form4-06082026_040610.xml","form_type":"4"}},{"id":745821,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":40388,"kind":"person","name":"Molineaux Christopher P.","position":1,"cik":"0001654773","reported_name":"Molineaux Christopher P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2026-06-08T20:15:14.000Z","date":"2026-06-04","kind":"grant","planned":false,"acquired":true,"shares":10987,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares underlying these restricted stock units will vest in one installment on June 4, 2027, subject to the Reporting Person's Continuous Service (as defined in the Plan) as of such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The shares underlying these restricted stock units will vest in one installment on June 4, 2027, subject to the Reporting Person's Continuous Service (as defined in the Plan) as of such date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"This grant was made pursuant to the issuer's tenth amended and restated non-employee director compensation policy."}],"balance_after":10987,"derivative":{"underlying":"Common Stock","underlying_shares":10987},"source":{"system":"sec-edgar","filing":"0001654773-26-000003","document":"form4-06082026_040610.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000165477326000003/form4-06082026_040610.xml","form_type":"4"}},{"id":745820,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":40388,"kind":"person","name":"Molineaux Christopher P.","position":1,"cik":"0001654773","reported_name":"Molineaux Christopher P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-08T20:15:14.000Z","date":"2026-06-04","kind":"grant","planned":false,"acquired":true,"shares":42350,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to this stock option will vest in twelve equal monthly installments commencing on July 4, 2026, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2025 Equity Incentive Plan, or the Plan) through each such vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"This grant was made pursuant to the issuer's tenth amended and restated non-employee director compensation policy."}],"balance_after":42350,"derivative":{"exercise_price":4.71,"expiration_date":"2036-06-03","underlying":"Common Stock","underlying_shares":42350},"source":{"system":"sec-edgar","filing":"0001654773-26-000003","document":"form4-06082026_040610.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000165477326000003/form4-06082026_040610.xml","form_type":"4"}},{"id":745819,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":40388,"kind":"person","name":"Molineaux Christopher P.","position":1,"cik":"0001654773","reported_name":"Molineaux Christopher P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-08T20:15:14.000Z","date":"2026-06-05","kind":"exercise","planned":false,"acquired":true,"shares":11580,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."}],"balance_after":69536,"source":{"system":"sec-edgar","filing":"0001654773-26-000003","document":"form4-06082026_040610.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000165477326000003/form4-06082026_040610.xml","form_type":"4"}},{"id":1117448,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":40388,"kind":"person","name":"Molineaux Christopher P.","position":1,"cik":"0001654773","reported_name":"Molineaux Christopher P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2025-06-09T20:20:12.000Z","date":"2025-06-06","kind":"exercise","planned":false,"acquired":false,"shares":4793,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The shares underlying these restricted stock units vested on June 6, 2025."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The shares underlying these restricted stock units vested on June 6, 2025."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":4793},"source":{"system":"sec-edgar","filing":"0001415889-25-016247","document":"form4-06092025_040601.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000141588925016247/form4-06092025_040601.xml","form_type":"4"}},{"id":1117447,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":40388,"kind":"person","name":"Molineaux Christopher P.","position":1,"cik":"0001654773","reported_name":"Molineaux Christopher P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2025-06-09T20:20:12.000Z","date":"2025-06-05","kind":"grant","planned":false,"acquired":true,"shares":11580,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares underlying these restricted stock units will vest in one installment on June 5, 2026, subject to the Reporting Person's Continuous Service (as defined in the Plan) as of such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The shares underlying these restricted stock units will vest in one installment on June 5, 2026, subject to the Reporting Person's Continuous Service (as defined in the Plan) as of such date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"This grant was made pursuant to the issuer's tenth amended and restated non-employee director compensation policy."}],"balance_after":11580,"derivative":{"underlying":"Common Stock","underlying_shares":11580},"source":{"system":"sec-edgar","filing":"0001415889-25-016247","document":"form4-06092025_040601.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000141588925016247/form4-06092025_040601.xml","form_type":"4"}},{"id":1117446,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":40388,"kind":"person","name":"Molineaux Christopher P.","position":1,"cik":"0001654773","reported_name":"Molineaux Christopher P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-09T20:20:12.000Z","date":"2025-06-05","kind":"grant","planned":false,"acquired":true,"shares":42350,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to this stock option will vest in twelve equal monthly installments commencing on July 5, 2025, subject to the Reporting Person's Continuous Service (as defined in the Plan) through each such vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"This grant was made pursuant to the issuer's tenth amended and restated non-employee director compensation policy."}],"balance_after":42350,"derivative":{"exercise_price":1.56,"expiration_date":"2035-06-04","underlying":"Common Stock","underlying_shares":42350},"source":{"system":"sec-edgar","filing":"0001415889-25-016247","document":"form4-06092025_040601.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000141588925016247/form4-06092025_040601.xml","form_type":"4"}},{"id":1117445,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":40388,"kind":"person","name":"Molineaux Christopher P.","position":1,"cik":"0001654773","reported_name":"Molineaux Christopher P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-09T20:20:12.000Z","date":"2025-06-06","kind":"exercise","planned":false,"acquired":true,"shares":4793,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."}],"balance_after":57956,"source":{"system":"sec-edgar","filing":"0001415889-25-016247","document":"form4-06092025_040601.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000141588925016247/form4-06092025_040601.xml","form_type":"4"}},{"id":1484520,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":40388,"kind":"person","name":"Molineaux Christopher P.","position":1,"cik":"0001654773","reported_name":"Molineaux Christopher P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2024-06-10T20:15:17.000Z","date":"2024-06-06","kind":"grant","planned":false,"acquired":true,"shares":4793,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares underlying these restricted stock units will vest on June 6, 2025, subject to the Reporting Person's continuous service through such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The shares underlying these restricted stock units will vest on June 6, 2025, subject to the Reporting Person's continuous service through such date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"This grant was made pursuant to the issuer's ninth amended and restated non-employee director compensation policy."}],"balance_after":4793,"derivative":{"underlying":"Common Stock","underlying_shares":4793},"source":{"system":"sec-edgar","filing":"0001415889-24-016194","document":"form4-06102024_040607.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000141588924016194/form4-06102024_040607.xml","form_type":"4"}},{"id":1484519,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":40388,"kind":"person","name":"Molineaux Christopher P.","position":1,"cik":"0001654773","reported_name":"Molineaux Christopher P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-10T20:15:17.000Z","date":"2024-06-06","kind":"grant","planned":false,"acquired":true,"shares":15750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option will vest in twelve equal monthly installments commencing July 6, 2024, subject to Reporting Person's continuous service through each such date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"This grant was made pursuant to the issuer's ninth amended and restated non-employee director compensation policy."}],"balance_after":15750,"derivative":{"exercise_price":1.03,"expiration_date":"2034-06-05","underlying":"Common Stock","underlying_shares":15750},"source":{"system":"sec-edgar","filing":"0001415889-24-016194","document":"form4-06102024_040607.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000141588924016194/form4-06102024_040607.xml","form_type":"4"}},{"id":1491465,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":40388,"kind":"person","name":"Molineaux Christopher P.","position":1,"cik":"0001654773","reported_name":"Molineaux Christopher P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2024-06-04T20:30:18.000Z","date":"2024-06-01","kind":"exercise","planned":false,"acquired":false,"shares":4660,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying these restricted stock units vested on June 1, 2024."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The shares underlying these restricted stock units vested on June 1, 2024."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":4660},"source":{"system":"sec-edgar","filing":"0001415889-24-015366","document":"form4-06042024_040614.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000141588924015366/form4-06042024_040614.xml","form_type":"4"}},{"id":1491464,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":40388,"kind":"person","name":"Molineaux Christopher P.","position":1,"cik":"0001654773","reported_name":"Molineaux Christopher P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-04T20:30:18.000Z","date":"2024-06-01","kind":"exercise","planned":false,"acquired":true,"shares":4660,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."}],"balance_after":53163,"source":{"system":"sec-edgar","filing":"0001415889-24-015366","document":"form4-06042024_040614.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000141588924015366/form4-06042024_040614.xml","form_type":"4"}},{"id":1846188,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":40388,"kind":"person","name":"Molineaux Christopher P.","position":1,"cik":"0001654773","reported_name":"Molineaux Christopher P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-22T20:32:22.000Z","date":"2023-06-20","kind":"exercise","planned":false,"acquired":false,"shares":16500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option vested in twelve equal monthly installments commencing July 4, 2020, subject to the reporting person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":0,"derivative":{"exercise_price":1.41,"expiration_date":"2030-06-03","underlying":"Common Stock","underlying_shares":16500},"source":{"system":"sec-edgar","filing":"0001209191-23-039080","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919123039080/doc4.xml","form_type":"4"}},{"id":1846187,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":40388,"kind":"person","name":"Molineaux Christopher P.","position":1,"cik":"0001654773","reported_name":"Molineaux Christopher P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-22T20:32:22.000Z","date":"2023-06-20","kind":"exercise","planned":false,"acquired":true,"shares":16500,"price":1.41,"value":23265.0,"ownership":{"direct":true},"balance_after":48503,"source":{"system":"sec-edgar","filing":"0001209191-23-039080","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919123039080/doc4.xml","form_type":"4"}},{"id":1848916,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":40388,"kind":"person","name":"Molineaux Christopher P.","position":1,"cik":"0001654773","reported_name":"Molineaux Christopher P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-20T20:31:10.000Z","date":"2023-06-15","kind":"exercise","planned":false,"acquired":false,"shares":198,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the shares underlying this option vested on December 8, 2015 and the remaining shares vested in 36 equal monthly installments thereafter, subject to the reporting person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":0,"derivative":{"exercise_price":1.52,"expiration_date":"2024-12-07","underlying":"Common Stock","underlying_shares":198},"source":{"system":"sec-edgar","filing":"0001209191-23-038409","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919123038409/doc4.xml","form_type":"4"}},{"id":1848915,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":40388,"kind":"person","name":"Molineaux Christopher P.","position":1,"cik":"0001654773","reported_name":"Molineaux Christopher P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-20T20:31:10.000Z","date":"2023-06-15","kind":"exercise","planned":false,"acquired":false,"shares":51,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares underlying this option vested on August 13, 2015 and the remaining shares vested in 36 equal monthly installments thereafter, subject to the reporting person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":0,"derivative":{"exercise_price":0.72,"expiration_date":"2024-08-12","underlying":"Common Stock","underlying_shares":51},"source":{"system":"sec-edgar","filing":"0001209191-23-038409","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919123038409/doc4.xml","form_type":"4"}},{"id":1848914,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":40388,"kind":"person","name":"Molineaux Christopher P.","position":1,"cik":"0001654773","reported_name":"Molineaux Christopher P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-20T20:31:10.000Z","date":"2023-06-15","kind":"exercise","planned":false,"acquired":true,"shares":198,"price":1.52,"value":300.96,"ownership":{"direct":true},"balance_after":32003,"source":{"system":"sec-edgar","filing":"0001209191-23-038409","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919123038409/doc4.xml","form_type":"4"}},{"id":1848913,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":40388,"kind":"person","name":"Molineaux Christopher P.","position":1,"cik":"0001654773","reported_name":"Molineaux Christopher P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-20T20:31:10.000Z","date":"2023-06-15","kind":"exercise","planned":false,"acquired":true,"shares":51,"price":0.72,"value":36.72,"ownership":{"direct":true},"balance_after":31805,"source":{"system":"sec-edgar","filing":"0001209191-23-038409","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919123038409/doc4.xml","form_type":"4"}},{"id":1866240,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":40388,"kind":"person","name":"Molineaux Christopher P.","position":1,"cik":"0001654773","reported_name":"Molineaux Christopher P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2023-06-05T21:02:01.000Z","date":"2023-06-02","kind":"exercise","planned":false,"acquired":false,"shares":4507,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The shares underlying these restricted stock units vested on June 2, 2023."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The shares underlying these restricted stock units vested on June 2, 2023."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":4507},"source":{"system":"sec-edgar","filing":"0001209191-23-034455","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919123034455/doc4.xml","form_type":"4"}},{"id":1866239,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":40388,"kind":"person","name":"Molineaux Christopher P.","position":1,"cik":"0001654773","reported_name":"Molineaux Christopher P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2023-06-05T21:02:01.000Z","date":"2023-06-01","kind":"grant","planned":false,"acquired":true,"shares":4660,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This grant was made pursuant to the issuer's ninth amended and restated non-employee director compensation policy."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares underlying these restricted stock units will vest on June 1, 2024, subject to the Reporting Person's continuous service through such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The shares underlying these restricted stock units will vest on June 1, 2024, subject to the Reporting Person's continuous service through such date."}],"balance_after":4660,"derivative":{"underlying":"Common Stock","underlying_shares":4660},"source":{"system":"sec-edgar","filing":"0001209191-23-034455","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919123034455/doc4.xml","form_type":"4"}},{"id":1866238,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":40388,"kind":"person","name":"Molineaux Christopher P.","position":1,"cik":"0001654773","reported_name":"Molineaux Christopher P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-05T21:02:01.000Z","date":"2023-06-01","kind":"grant","planned":false,"acquired":true,"shares":15750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This grant was made pursuant to the issuer's ninth amended and restated non-employee director compensation policy."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares subject to this option will vest in twelve equal monthly installments commencing July 1, 2023, subject to Reporting Person's continuous service through each such date."}],"balance_after":15750,"derivative":{"exercise_price":8.7,"expiration_date":"2033-05-31","underlying":"Common Stock","underlying_shares":15750},"source":{"system":"sec-edgar","filing":"0001209191-23-034455","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919123034455/doc4.xml","form_type":"4"}},{"id":1866237,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":40388,"kind":"person","name":"Molineaux Christopher P.","position":1,"cik":"0001654773","reported_name":"Molineaux Christopher P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-05T21:02:01.000Z","date":"2023-06-02","kind":"exercise","planned":false,"acquired":true,"shares":4507,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."}],"balance_after":31754,"source":{"system":"sec-edgar","filing":"0001209191-23-034455","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919123034455/doc4.xml","form_type":"4"}},{"id":2241424,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":40388,"kind":"person","name":"Molineaux Christopher P.","position":1,"cik":"0001654773","reported_name":"Molineaux Christopher P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2022-06-06T21:27:00.000Z","date":"2022-06-03","kind":"exercise","acquired":false,"shares":3356,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The shares underlying these restricted stock units vested on June 3, 2022."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The shares underlying these restricted stock units vested on June 3, 2022."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":3356},"source":{"system":"sec-edgar","filing":"0001209191-22-034596","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919122034596/doc4.xml","form_type":"4"}},{"id":2241423,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":40388,"kind":"person","name":"Molineaux Christopher P.","position":1,"cik":"0001654773","reported_name":"Molineaux Christopher P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2022-06-06T21:27:00.000Z","date":"2022-06-02","kind":"grant","acquired":true,"shares":4507,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This grant was made pursuant to the issuer's seventh amended and restated non-employee director compensation policy."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares underlying these restricted stock units will vest on June 2, 2023, subject to the Reporting Person's continuous service through such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The shares underlying these restricted stock units will vest on June 2, 2023, subject to the Reporting Person's continuous service through such date."}],"balance_after":4507,"derivative":{"underlying":"Common Stock","underlying_shares":4507},"source":{"system":"sec-edgar","filing":"0001209191-22-034596","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919122034596/doc4.xml","form_type":"4"}},{"id":2241422,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":40388,"kind":"person","name":"Molineaux Christopher P.","position":1,"cik":"0001654773","reported_name":"Molineaux Christopher P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-06T21:27:00.000Z","date":"2022-06-02","kind":"grant","acquired":true,"shares":15750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This grant was made pursuant to the issuer's seventh amended and restated non-employee director compensation policy."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares subject to this option will vest in twelve equal monthly installments commencing July 2, 2022, subject to Reporting Person's continuous service through each such date."}],"balance_after":15750,"derivative":{"exercise_price":14.48,"expiration_date":"2032-06-01","underlying":"Common Stock","underlying_shares":15750},"source":{"system":"sec-edgar","filing":"0001209191-22-034596","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919122034596/doc4.xml","form_type":"4"}},{"id":2241421,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":40388,"kind":"person","name":"Molineaux Christopher P.","position":1,"cik":"0001654773","reported_name":"Molineaux Christopher P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-06-06T21:27:00.000Z","date":"2022-06-03","kind":"exercise","acquired":true,"shares":3356,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."}],"balance_after":27247,"source":{"system":"sec-edgar","filing":"0001209191-22-034596","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919122034596/doc4.xml","form_type":"4"}},{"id":2680484,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":40388,"kind":"person","name":"Molineaux Christopher P.","position":1,"cik":"0001654773","reported_name":"Molineaux Christopher P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2021-06-05T00:05:10.000Z","date":"2021-06-03","kind":"grant","acquired":true,"shares":3356,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This grant was made pursuant to the issuer's fifth amended and restated non-employee director compensation policy."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares underlying these restricted stock units will vest on June 3, 2022, subject to the Reporting Person's continuous service through such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The shares underlying these restricted stock units will vest on June 3, 2022, subject to the Reporting Person's continuous service through such date."}],"balance_after":3356,"derivative":{"underlying":"Common Stock","underlying_shares":3356},"source":{"system":"sec-edgar","filing":"0001209191-21-038452","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919121038452/doc4.xml","form_type":"4"}},{"id":2680483,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":40388,"kind":"person","name":"Molineaux Christopher P.","position":1,"cik":"0001654773","reported_name":"Molineaux Christopher P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-05T00:05:10.000Z","date":"2021-06-03","kind":"grant","acquired":true,"shares":12250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This grant was made pursuant to the issuer's fifth amended and restated non-employee director compensation policy."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject this option will vest in twelve equal monthly installments commencing July 3, 2021, subject to Reporting Person's continuous service through each such date."}],"balance_after":12250,"derivative":{"exercise_price":21.9,"expiration_date":"2031-06-02","underlying":"Common Stock","underlying_shares":12250},"source":{"system":"sec-edgar","filing":"0001209191-21-038452","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919121038452/doc4.xml","form_type":"4"}},{"id":3118141,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":40388,"kind":"person","name":"Molineaux Christopher P.","position":1,"cik":"0001654773","reported_name":"Molineaux Christopher P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2020-06-08T21:31:20.000Z","date":"2020-06-06","kind":"exercise","acquired":false,"shares":7333,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"shares","element":"transactionShares","label":"F3","text":"This grant was made pursuant to the issuer's amended and restated non-employee director compensation policy."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares underlying these restricted stock units vested on June 6, 2020."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The shares underlying these restricted stock units vested on June 6, 2020."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":7333},"source":{"system":"sec-edgar","filing":"0001209191-20-035034","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919120035034/doc4.xml","form_type":"4"}},{"id":3118140,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":40388,"kind":"person","name":"Molineaux Christopher P.","position":1,"cik":"0001654773","reported_name":"Molineaux Christopher P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option Grant (right to buy)","published_at":"2020-06-08T21:31:20.000Z","date":"2020-06-04","kind":"grant","acquired":true,"shares":16500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject this option will vest in twelve equal monthly installments commencing July 4, 2020, subject to Reporting Person's continuous service through each such date."}],"balance_after":16500,"derivative":{"exercise_price":1.41,"expiration_date":"2030-06-03","underlying":"Common Stock","underlying_shares":16500},"source":{"system":"sec-edgar","filing":"0001209191-20-035034","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919120035034/doc4.xml","form_type":"4"}},{"id":3118139,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":40388,"kind":"person","name":"Molineaux Christopher P.","position":1,"cik":"0001654773","reported_name":"Molineaux Christopher P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-06-08T21:31:20.000Z","date":"2020-06-06","kind":"exercise","acquired":true,"shares":7333,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."}],"balance_after":23891,"source":{"system":"sec-edgar","filing":"0001209191-20-035034","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919120035034/doc4.xml","form_type":"4"}},{"id":3226472,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":40388,"kind":"person","name":"Molineaux Christopher P.","position":1,"cik":"0001654773","reported_name":"Molineaux Christopher P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted stock units","published_at":"2020-03-04T21:26:21.000Z","date":"2020-03-02","kind":"exercise","acquired":false,"shares":8876,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying these restricted stock units vest immediately."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The shares underlying these restricted stock units vest immediately."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":8876},"source":{"system":"sec-edgar","filing":"0001209191-20-016084","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919120016084/doc4.xml","form_type":"4"}},{"id":3226471,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":40388,"kind":"person","name":"Molineaux Christopher P.","position":1,"cik":"0001654773","reported_name":"Molineaux Christopher P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted stock units","published_at":"2020-03-04T21:26:21.000Z","date":"2020-03-02","kind":"grant","acquired":true,"shares":8876,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying these restricted stock units vest immediately."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The shares underlying these restricted stock units vest immediately."}],"balance_after":8876,"derivative":{"underlying":"Common Stock","underlying_shares":8876},"source":{"system":"sec-edgar","filing":"0001209191-20-016084","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919120016084/doc4.xml","form_type":"4"}},{"id":3226470,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":40388,"kind":"person","name":"Molineaux Christopher P.","position":1,"cik":"0001654773","reported_name":"Molineaux Christopher P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-03-04T21:26:21.000Z","date":"2020-03-02","kind":"exercise","acquired":true,"shares":8876,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."}],"balance_after":16558,"source":{"system":"sec-edgar","filing":"0001209191-20-016084","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919120016084/doc4.xml","form_type":"4"}},{"id":3495342,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":40388,"kind":"person","name":"Molineaux Christopher P.","position":1,"cik":"0001654773","reported_name":"Molineaux Christopher P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2019-06-10T20:52:28.000Z","date":"2019-06-06","kind":"grant","acquired":true,"shares":7333,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"shares","element":"transactionShares","label":"F2","text":"This grant was made pursuant to the issuer's amended and restated non-employee director compensation policy."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares underlying these restricted stock units vest on June 6, 2020, subject to the Reporting Person's continuous service with the issuer as of the vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The shares underlying these restricted stock units vest on June 6, 2020, subject to the Reporting Person's continuous service with the issuer as of the vesting date."}],"balance_after":7333,"derivative":{"underlying":"Common Stock","underlying_shares":7333},"source":{"system":"sec-edgar","filing":"0001209191-19-035835","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919119035835/doc4.xml","form_type":"4"}},{"id":3899548,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":40388,"kind":"person","name":"Molineaux Christopher P.","position":1,"cik":"0001654773","reported_name":"Molineaux Christopher P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2018-06-08T20:02:04.000Z","date":"2018-06-07","kind":"grant","acquired":true,"shares":8000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This grant was made pursuant to the issuer's non-employee director compensation policy."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying this option vest in twelve equal monthly installments through June 7, 2019, subject to the reporting person's continuous service as of such vesting date."}],"balance_after":8000,"derivative":{"exercise_price":18.35,"expiration_date":"2028-06-06","underlying":"Common Stock","underlying_shares":8000},"source":{"system":"sec-edgar","filing":"0001209191-18-036651","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919118036651/doc4.xml","form_type":"4"}},{"id":3966820,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":40388,"kind":"person","name":"Molineaux Christopher P.","position":1,"cik":"0001654773","reported_name":"Molineaux Christopher P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-04-09T20:50:06.000Z","date":"2018-04-06","kind":"sale","acquired":true,"shares":2300,"price":16.52,"value":37996.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the record holder of the securities on March 20, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $16.24 to $16.88, inclusive. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected."}],"balance_after":7682,"source":{"system":"sec-edgar","filing":"0001209191-18-024355","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919118024355/doc4.xml","form_type":"4"}},{"id":3984763,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":40388,"kind":"person","name":"Molineaux Christopher P.","position":1,"cik":"0001654773","reported_name":"Molineaux Christopher P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2018-03-22T20:35:41.000Z","date":"2018-03-20","kind":"exercise","acquired":false,"shares":264,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the shares underlying this option vested on December 8, 2015 and the remaining shares vest in 36 equal monthly installments thereafter, subject to the reporting person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":198,"derivative":{"exercise_price":1.52,"expiration_date":"2024-12-07","underlying":"Common Stock","underlying_shares":264},"source":{"system":"sec-edgar","filing":"0001209191-18-021261","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919118021261/doc4.xml","form_type":"4"}},{"id":3984762,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":40388,"kind":"person","name":"Molineaux Christopher P.","position":1,"cik":"0001654773","reported_name":"Molineaux Christopher P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2018-03-22T20:35:41.000Z","date":"2018-03-20","kind":"exercise","acquired":false,"shares":120,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the shares underlying this option vested on August 13, 2015 and the remaining shares vest in 36 equal monthly installments thereafter, subject to the reporting person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":51,"derivative":{"exercise_price":0.72,"expiration_date":"2024-08-12","underlying":"Common Stock","underlying_shares":120},"source":{"system":"sec-edgar","filing":"0001209191-18-021261","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919118021261/doc4.xml","form_type":"4"}},{"id":3984761,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":40388,"kind":"person","name":"Molineaux Christopher P.","position":1,"cik":"0001654773","reported_name":"Molineaux Christopher P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2018-03-22T20:35:41.000Z","date":"2018-03-20","kind":"exercise","acquired":false,"shares":1993,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares underlying this option vested on January 29, 2015 and the remaining shares vest in 36 equal monthly installments thereafter, subject to the reporting person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":0,"derivative":{"exercise_price":0.41,"expiration_date":"2024-01-28","underlying":"Common Stock","underlying_shares":1993},"source":{"system":"sec-edgar","filing":"0001209191-18-021261","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919118021261/doc4.xml","form_type":"4"}},{"id":3984760,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":40388,"kind":"person","name":"Molineaux Christopher P.","position":1,"cik":"0001654773","reported_name":"Molineaux Christopher P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-03-22T20:35:41.000Z","date":"2018-03-20","kind":"exercise","acquired":true,"shares":264,"price":1.52,"value":401.28,"ownership":{"direct":true},"balance_after":9982,"source":{"system":"sec-edgar","filing":"0001209191-18-021261","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919118021261/doc4.xml","form_type":"4"}},{"id":3984759,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":40388,"kind":"person","name":"Molineaux Christopher P.","position":1,"cik":"0001654773","reported_name":"Molineaux Christopher P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-03-22T20:35:41.000Z","date":"2018-03-20","kind":"exercise","acquired":true,"shares":120,"price":0.72,"value":86.4,"ownership":{"direct":true},"balance_after":9718,"source":{"system":"sec-edgar","filing":"0001209191-18-021261","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919118021261/doc4.xml","form_type":"4"}},{"id":3984758,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":40388,"kind":"person","name":"Molineaux Christopher P.","position":1,"cik":"0001654773","reported_name":"Molineaux Christopher P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-03-22T20:35:41.000Z","date":"2018-03-20","kind":"exercise","acquired":true,"shares":1993,"price":0.41,"value":817.13,"ownership":{"direct":true},"balance_after":9598,"source":{"system":"sec-edgar","filing":"0001209191-18-021261","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919118021261/doc4.xml","form_type":"4"}},{"id":4278633,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":40388,"kind":"person","name":"Molineaux Christopher P.","position":1,"cik":"0001654773","reported_name":"Molineaux Christopher P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2017-06-16T23:44:23.000Z","date":"2017-06-15","kind":"grant","acquired":true,"shares":8000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option vest in twelve equal monthly installments through June 15, 2018, subject to the reporting person's continuous service as of such vesting date."}],"balance_after":8000,"derivative":{"exercise_price":24.58,"expiration_date":"2027-06-14","underlying":"Common Stock","underlying_shares":8000},"source":{"system":"sec-edgar","filing":"0001209191-17-040671","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919117040671/doc4.xml","form_type":"4"}},{"id":4376148,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":40388,"kind":"person","name":"Molineaux Christopher P.","position":1,"cik":"0001654773","reported_name":"Molineaux Christopher P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2017-03-22T00:43:35.000Z","date":"2017-03-17","kind":"exercise","acquired":false,"shares":311,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the shares underlying this option vested on August 13, 2015 and the remaining shares vest in 36 equal monthly installments thereafter, subject to the reporting person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":171,"derivative":{"exercise_price":0.72,"expiration_date":"2024-08-12","underlying":"Common Stock","underlying_shares":311},"source":{"system":"sec-edgar","filing":"0001209191-17-022143","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919117022143/doc4.xml","form_type":"4"}},{"id":4376147,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":40388,"kind":"person","name":"Molineaux Christopher P.","position":1,"cik":"0001654773","reported_name":"Molineaux Christopher P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2017-03-22T00:43:35.000Z","date":"2017-03-17","kind":"exercise","acquired":false,"shares":592,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the shares underlying this option vested on December 8, 2015 and the remaining shares vest in 36 equal monthly installments thereafter, subject to the reporting person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":462,"derivative":{"exercise_price":1.52,"expiration_date":"2024-12-07","underlying":"Common Stock","underlying_shares":592},"source":{"system":"sec-edgar","filing":"0001209191-17-022143","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919117022143/doc4.xml","form_type":"4"}},{"id":4376146,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":40388,"kind":"person","name":"Molineaux Christopher P.","position":1,"cik":"0001654773","reported_name":"Molineaux Christopher P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2017-03-22T00:43:35.000Z","date":"2017-03-17","kind":"exercise","acquired":false,"shares":6702,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares underlying this option vested on January 29, 2015 and the remaining shares vest in 36 equal monthly installments thereafter, subject to the reporting person's continued service with the Issuer as of the applicable vesting date."}],"balance_after":1993,"derivative":{"exercise_price":0.41,"expiration_date":"2024-01-28","underlying":"Common Stock","underlying_shares":6702},"source":{"system":"sec-edgar","filing":"0001209191-17-022143","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919117022143/doc4.xml","form_type":"4"}},{"id":4376145,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":40388,"kind":"person","name":"Molineaux Christopher P.","position":1,"cik":"0001654773","reported_name":"Molineaux Christopher P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-03-22T00:43:35.000Z","date":"2017-03-17","kind":"exercise","acquired":true,"shares":311,"price":0.72,"value":223.92,"ownership":{"direct":true},"balance_after":7605,"source":{"system":"sec-edgar","filing":"0001209191-17-022143","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919117022143/doc4.xml","form_type":"4"}},{"id":4376144,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":40388,"kind":"person","name":"Molineaux Christopher P.","position":1,"cik":"0001654773","reported_name":"Molineaux Christopher P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-03-22T00:43:35.000Z","date":"2017-03-17","kind":"exercise","acquired":true,"shares":592,"price":1.52,"value":899.84,"ownership":{"direct":true},"balance_after":7294,"source":{"system":"sec-edgar","filing":"0001209191-17-022143","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919117022143/doc4.xml","form_type":"4"}},{"id":4376143,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":40388,"kind":"person","name":"Molineaux Christopher P.","position":1,"cik":"0001654773","reported_name":"Molineaux Christopher P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-03-22T00:43:35.000Z","date":"2017-03-17","kind":"exercise","acquired":true,"shares":6702,"price":0.41,"value":2747.82,"ownership":{"direct":true},"balance_after":6702,"source":{"system":"sec-edgar","filing":"0001209191-17-022143","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1557746/000120919117022143/doc4.xml","form_type":"4"}}]}